First and repeat rebiopsy for detecting EGFR T790M mutation in non-small-cell lung cancer: CS-Lung-003 prospective observational registry study
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-021-03893-z
Abstract: Osimertinib is still essential for the treatment of epidermal growth factor receptor (EGFR)-T790M-positive non-small-cell lung cancer (NSCLC) even in a relapsed setting, which suggests the importance of rebiopsy. The clinical value of repeat rebiopsy in… read more here.
Keywords: rebiopsy; lung; first rebiopsy; repeat rebiopsy ... See more keywords
Real-world data on efficacy and safety of osimertinib in non-small cell lung cancer patients with EGFR T790M mutation detected by first and repeat rebiopsy.
Sign Up to like & getrecommendations! Published in 2023 at "Asia-Pacific journal of clinical oncology"
DOI: 10.1111/ajco.13935
Abstract: BACKGROUND Osimertinib could effectively target epidermal growth factor receptor (EGFR) T790M resistance mutations in non-small cell lung cancer (NSCLC), indicating that rebiopsy may be particularly important. However, the clinical benefit of repeat rebiopsy in T790M-negative… read more here.
Keywords: osimertinib; t790m positive; repeat rebiopsy; rebiopsy ... See more keywords
Accuracy of transbronchial biopsy as a rebiopsy method for patients with relapse of advanced non-small-cell lung cancer after systemic chemotherapy
Sign Up to like & getrecommendations! Published in 2017 at "BMJ Open Respiratory Research"
DOI: 10.1136/bmjresp-2016-000163
Abstract: Introduction Rebiopsy in patients with advanced non-small-cell lung cancer (NSCLC) resistant to systemic chemotherapy may yield information on the mechanisms of resistance and planning of subsequent treatment. Transbronchial biopsy (TBB) using a flexible bronchoscope has… read more here.
Keywords: chemotherapy; rebiopsy; systemic chemotherapy; lung cancer ... See more keywords
Rebiopsy status among non-small cell lung cancer patients after Icotinib therapy in China.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e21146
Abstract: e21146Background: Acquired T790M mutation accounts for 50-60% of TKI resistant mechanism in EGFR mutation (+) NSCLC patients progressed after TKIs. Rebiopsy was recommend in these patients to detect the T790M mutation. Icotinib was a first-generation… read more here.
Keywords: icotinib therapy; rebiopsy; china; rebiopsy status ... See more keywords
Benefit of rebiopsy for deciding treatment strategy in rectal cancer: A case report.
Sign Up to like & getrecommendations! Published in 2017 at "Oncology letters"
DOI: 10.3892/ol.2017.6601
Abstract: Rebiopsy is considered an option for specific types of cancer, such as breast, non-small cell lung, and prostate cancer, in clinical trials and in practice. The benefit of rebiopsy comes from the selection of a… read more here.
Keywords: benefit rebiopsy; case; treatment strategy; rebiopsy ... See more keywords